AbbVie ABBV stock has declined 12.6% in the past three months. The stock is also trading below its 50-day and 200-day moving ...

AbbVie has also submitted an application to the FDA, seeking the label expansion for Skyrizi to include the UC indication in the United States. The regulatory filing is yet to be accepted for review.

Physicians have delivered a boost to AbbVie’s hopes of turning Skyrizi into a $17-billion-a-year drug. The 101 gastroenterologists polled by Spherix Global Insights talked up Skyrizi’s promise ...

The regulatory nod goes to risankizumab, a drug that North Chicago, Illinois-based AbbVie already sells under the name “Skyrizi” for approved uses in plaque psoriasis and psoriatic arthritis.

AbbVie posted strong Q1 2025 results and raised guidance, but early-stage obesity pipeline and fair valuation limit upside.

Offsetting Humira's expected declines, AbbVie looks well-positioned with next-generation immunology drugs. In particular, recently launched drugs Skyrizi and Rinvoq have shown improved efficacy ...

AbbVie continued to benefit from strong sales growth for Rinvoq and Skyrizi. The company’s outlook was also better than the estimates, faring well for its stock. Separately, see What’s Next ...

AbbVie has received European Commission approval of its anti-inflammation drug Skyrizi for the treatment of adult patients with moderately to severely active ulcerative colitis, the pharmaceutical ...

Drug now approved for four conditions across different inflammatory diseases Drug maker AbbVie Inc. on Tuesday said the Food and Drug Administration had approved its drug Skyrizi for adults with ...

Humira revenues were $2.23 billion (down 37.2%), Skyrizi sales reached $3.21 billion (up 50.8%), and Rinvoq revenues were $1.61 billion (up 45.3%). Also Read: FDA Approves AbbVie’s Parkinson ...

While that still stings, Skyrizi and Rinvoq are putting a salve on the wound. AbbVie has been looking for drugs to replace Humira, which was long its biggest revenue contributor, but since losing ...